416 related articles for article (PubMed ID: 27384305)
1. Male 11β-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease.
Larner DP; Morgan SA; Gathercole LL; Doig CL; Guest P; Weston C; Hazeldine J; Tomlinson JW; Stewart PM; Lavery GG
Endocrinology; 2016 Sep; 157(9):3493-504. PubMed ID: 27384305
[TBL] [Abstract][Full Text] [Related]
2. A switch in hepatic cortisol metabolism across the spectrum of non alcoholic fatty liver disease.
Ahmed A; Rabbitt E; Brady T; Brown C; Guest P; Bujalska IJ; Doig C; Newsome PN; Hubscher S; Elias E; Adams DH; Tomlinson JW; Stewart PM
PLoS One; 2012; 7(2):e29531. PubMed ID: 22363403
[TBL] [Abstract][Full Text] [Related]
3. 11-Dehydrocorticosterone causes metabolic syndrome, which is prevented when 11β-HSD1 is knocked out in livers of male mice.
Harno E; Cottrell EC; Keevil BG; DeSchoolmeester J; Bohlooly-Y M; Andersén H; Turnbull AV; Leighton B; White A
Endocrinology; 2013 Oct; 154(10):3599-609. PubMed ID: 23832962
[TBL] [Abstract][Full Text] [Related]
4. Dietary fatty acid composition alters 11β-hydroxysteroid dehydrogenase type 1 gene expression in rat retroperitoneal white adipose tissue.
Vara Prasad SS; Jeya Kumar SS; Kumar PU; Qadri SS; Vajreswari A
Lipids Health Dis; 2010 Oct; 9():111. PubMed ID: 20932307
[TBL] [Abstract][Full Text] [Related]
5. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
[TBL] [Abstract][Full Text] [Related]
6. Lack of significant metabolic abnormalities in mice with liver-specific disruption of 11β-hydroxysteroid dehydrogenase type 1.
Lavery GG; Zielinska AE; Gathercole LL; Hughes B; Semjonous N; Guest P; Saqib K; Sherlock M; Reynolds G; Morgan SA; Tomlinson JW; Walker EA; Rabbitt EH; Stewart PM
Endocrinology; 2012 Jul; 153(7):3236-48. PubMed ID: 22555437
[TBL] [Abstract][Full Text] [Related]
7. Effects of antisense-mediated inhibition of 11β-hydroxysteroid dehydrogenase type 1 on hepatic lipid metabolism.
Li G; Hernandez-Ono A; Crooke RM; Graham MJ; Ginsberg HN
J Lipid Res; 2011 May; 52(5):971-81. PubMed ID: 21364201
[TBL] [Abstract][Full Text] [Related]
8. 11β-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess.
Morgan SA; McCabe EL; Gathercole LL; Hassan-Smith ZK; Larner DP; Bujalska IJ; Stewart PM; Tomlinson JW; Lavery GG
Proc Natl Acad Sci U S A; 2014 Jun; 111(24):E2482-91. PubMed ID: 24889609
[TBL] [Abstract][Full Text] [Related]
9. Selective Inhibition of 11β-Hydroxysteroid Dehydrogenase Type 1 Attenuates High-Fat Diet-Induced Hepatic Steatosis in Mice.
Li H; Sheng J; Wang J; Gao H; Yu J; Ding G; Ding N; He W; Zha J
Drug Des Devel Ther; 2021; 15():2309-2324. PubMed ID: 34103895
[TBL] [Abstract][Full Text] [Related]
10. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
Morton NM; Seckl JR
Front Horm Res; 2008; 36():146-164. PubMed ID: 18230901
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of 11β-hydroxysteroid dehydrogenase type 1 in visceral adipose tissue and portal hypercortisolism in non-alcoholic fatty liver disease.
Candia R; Riquelme A; Baudrand R; Carvajal CA; Morales M; Solís N; Pizarro M; Escalona A; Carrasco G; Boza C; Pérez G; Padilla O; Cerda J; Fardella CE; Arrese M
Liver Int; 2012 Mar; 32(3):392-9. PubMed ID: 22136330
[TBL] [Abstract][Full Text] [Related]
12. Development of hepatocellular carcinoma in a murine model of nonalcoholic steatohepatitis induced by use of a high-fat/fructose diet and sedentary lifestyle.
Dowman JK; Hopkins LJ; Reynolds GM; Nikolaou N; Armstrong MJ; Shaw JC; Houlihan DD; Lalor PF; Tomlinson JW; Hübscher SG; Newsome PN
Am J Pathol; 2014 May; 184(5):1550-61. PubMed ID: 24650559
[TBL] [Abstract][Full Text] [Related]
13. 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors still improve metabolic phenotype in male 11β-HSD1 knockout mice suggesting off-target mechanisms.
Harno E; Cottrell EC; Yu A; DeSchoolmeester J; Gutierrez PM; Denn M; Swales JG; Goldberg FW; Bohlooly-Y M; Andersén H; Wild MJ; Turnbull AV; Leighton B; White A
Endocrinology; 2013 Dec; 154(12):4580-93. PubMed ID: 24169553
[TBL] [Abstract][Full Text] [Related]
14. 11β-HSD1 Inhibitor Alleviates Non-Alcoholic Fatty Liver Disease by Activating the AMPK/SIRT1 Signaling Pathway.
Chen Y; Li J; Zhang M; Yang W; Qin W; Zheng Q; Chu Y; Wu Y; Wu D; Yuan X
Nutrients; 2022 Jun; 14(11):. PubMed ID: 35684158
[TBL] [Abstract][Full Text] [Related]
15. Integrated omics analysis for characterization of the contribution of high fructose corn syrup to non-alcoholic fatty liver disease in obesity.
Papadopoulos G; Legaki AI; Georgila K; Vorkas P; Giannousi E; Stamatakis G; Moustakas II; Petrocheilou M; Pyrina I; Gercken B; Kassi E; Chavakis T; Pateras IS; Panayotou G; Gika H; Samiotaki M; Eliopoulos AG; Chatzigeorgiou A
Metabolism; 2023 Jul; 144():155552. PubMed ID: 36996933
[TBL] [Abstract][Full Text] [Related]
16. Saturated fat and cholesterol are critical to inducing murine metabolic syndrome with robust nonalcoholic steatohepatitis.
Mells JE; Fu PP; Kumar P; Smith T; Karpen SJ; Anania FA
J Nutr Biochem; 2015 Mar; 26(3):285-92. PubMed ID: 25577467
[TBL] [Abstract][Full Text] [Related]
17. Dietary manipulation reveals an unexpected inverse relationship between fat mass and adipose 11β-hydroxysteroid dehydrogenase type 1.
Man TY; Michailidou Z; Gokcel A; Ramage L; Chapman KE; Kenyon CJ; Seckl JR; Morton NM
Am J Physiol Endocrinol Metab; 2011 Jun; 300(6):E1076-84. PubMed ID: 21406612
[TBL] [Abstract][Full Text] [Related]
18. Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.
Masuzaki H; Flier JS
Curr Drug Targets Immune Endocr Metabol Disord; 2003 Dec; 3(4):255-62. PubMed ID: 14683456
[TBL] [Abstract][Full Text] [Related]
19. Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice.
Nuotio-Antar AM; Hachey DL; Hasty AH
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1517-28. PubMed ID: 17878220
[TBL] [Abstract][Full Text] [Related]
20. Vitamin A decreases pre-receptor amplification of glucocorticoids in obesity: study on the effect of vitamin A on 11beta-hydroxysteroid dehydrogenase type 1 activity in liver and visceral fat of WNIN/Ob obese rats.
Sakamuri VP; Ananthathmakula P; Veettil GN; Ayyalasomayajula V
Nutr J; 2011 Jun; 10():70. PubMed ID: 21696642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
